# Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin β1/Src/Akt-Driven Bypass Signaling

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/erlotinib-resistance-in-lung-cancer-cells-mediated-by-integrin-1-src-akt-driven/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Rina Kanda,Akihiko Kawahara,Kosuke Watari,Yûichi Murakami,Kahori Sonoda,Masashi Maeda,Hideaki Fujita,Masayoshi Kage,Hidetaka Uramoto,Carlota Costa,Michihiko Kuwano,Mayumi Ono |
| Citations | 166 |
| DOI | 10.1158/0008-5472.can-12-4502 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2108688207 |
| PMID | 23872583 |
| Type | article |
| Year | 2013 |

## Paper authors

- [Hidetaka Uramoto](https://scholariq.org/researchers/hidetaka-uramoto/)

## Paper journal

- [Cancer Research](https://scholariq.org/journals/cancer-research/)

## Paper primary topic

- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

## Paper topics

- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cell Adhesion Molecules Research](https://scholariq.org/topics/cell-adhesion-molecules-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.